Skip to content

Realizing potential through technology

We continue to explore new science, technology and methods to address ever-changing health challenges

Main Product

Innovative platform of enterovirus and influenza VLP vaccines

Influenza vaccines Development

1st generation
Egg-based inactivated Vaccines

• Takes 20 weeks to produce
• Need live virus
• Mutations in HA

2nd generation
Cell-based inactivated Vaccines

• Takes 16 weeks to produce
• Need live virus
• Few mutations in HA

3rd generation
Recombinant Protein Vaccines

• Reduce to only 12 weeks production
• No mutations in HA
• No live viruses
• Ready for emerging viruses (novel influenza, etc.)

Market Share %

Egg-based inactivated Vaccines

~85%

Cell-based inactivated Vaccines

~10%

Recombinant Protein Vaccines

~5% subunit HA (rHA, Flublok, too expensive)

Current Recombinant Protein flu Vaccine Development

Company Platforms HA antigen doses

NHRI Spin-off

VLP using Insect cells (Sf21 and Hi5)

15-30 µg/strain

Sanofi*
rHA using Insect cell (Sf9)
45 µg/strain
Medicago (bankruptcy in 2023)
VLP using plant (tobacco plant)
30 µg/strain
Novavax
rHA using Insect cell (Sf9)
60 µg/strain with adjuvant

Enterovirus Vaccines Development

Monovalent

Current monovalent EV71 vaccines is available in Taiwan, China & Indonesia. In Taiwan, NHRI developed and licensed to AdImmune & Medigen.

Multivalent

High-growth EV71 virus patent was approved in China, Malaysia & Taiwan. Reverse genetics patent is under preparation

Multivalent EV vaccines

We adapted a high-growth EV71 genotype B5 (HG-B5) virus after multiple passages and plaque selections in Vero cells and the HG-B5 virus could reach high titers (>108 TCID50/mL) in a microcarrier-based cell culture system. The viral particles were further puri- fied and formulated with alum adjuvant. After two doses of intramuscular immunization in rabbits, the HG-B5 vaccine candidate could induce cross-reactive neutralizing antibodies against the three major EV71 genogroups. In conclusion, a high-growth EV71 virus was successfully adapted in Vero cells and could induce broad spectrum neutralizing antibody titers against three (A, B5, and C4) genotypes in rabbits. Ó 2018

Contact Us

TaiU | Designed by tessera 2024 © All Rights Reserved.